Production and functional analysis of a phage displayed scFv recombinant antibody targeting EGFR/HER2 dimerization domain

Tumor cells exploit epidermal growth factor receptor (EGFR) family to develop resistance against therapeutic antibodies, such as Herceptin. Upon ligand binding, dimerization between EGFR and HER2 is one of the most important causes of treatment failure in breast cancer and other cancers expressing E...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Protein expression and purification Jg. 228; S. 106649
Hauptverfasser:	Dabiri, Mina, Tehrani, Mohsen, Rafiei, Alireza, Valadan, Reza
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Elsevier Inc 01.04.2025
Schlagworte:	Animals Cell Line, Tumor Cell Proliferation - drug effects Chlorocebus aethiops Dimerization domain EGFR ErbB receptor ErbB Receptors - antagonists & inhibitors ErbB Receptors - chemistry ErbB Receptors - genetics ErbB Receptors - immunology ErbB Receptors - metabolism HER2 Humans MCF-7 Cells Phosphorylation Protein Multimerization - drug effects Receptor, ErbB-2 - antagonists & inhibitors Receptor, ErbB-2 - chemistry Receptor, ErbB-2 - genetics Receptor, ErbB-2 - immunology Receptor, ErbB-2 - metabolism Recombinant Proteins - biosynthesis Recombinant Proteins - chemistry Recombinant Proteins - genetics Recombinant Proteins - immunology Recombinant Proteins - isolation & purification Recombinant Proteins - pharmacology scFv Single-Chain Antibodies - biosynthesis Single-Chain Antibodies - chemistry Single-Chain Antibodies - genetics Single-Chain Antibodies - isolation & purification Single-Chain Antibodies - pharmacology STAT3 Transcription Factor - metabolism Dimerization domain ErbB receptor HER2 scFv EGFR
ISSN:	1046-5928, 1096-0279, 1096-0279
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Tumor cells exploit epidermal growth factor receptor (EGFR) family to develop resistance against therapeutic antibodies, such as Herceptin. Upon ligand binding, dimerization between EGFR and HER2 is one of the most important causes of treatment failure in breast cancer and other cancers expressing EGFR and HER2. The aim of this study was to develop and evaluate the function of a human recombinant single-chain variable fragment (scFv) antibody against the dimerization domain of EGFR to inhibit its interaction with other members of the epidermal growth factor receptor family, especially HER2. scFv against EGFR was expressed and purified. Cell-ELISA, MTT assay, inhibition of STAT3 phosphorylation, quantitative RT-PCR, and dimerization inhibition were performed on EGFR and HER2 expressing cell lines to characterize functional properties of the produced scFv. The conformational structure of the produced scFv and its binding ability to EGFR was computationally investigated. In vitro binding analysis by cell-ELISA revealed the EGFR binding ability of the purified antibodies and confirmed by immunoblotting. ScFvs preferentially reduced the proliferation and survival of MCF7, MDA-MB-468, and SKOV3 cell lines with no effect on the VERO line. More considerably, MCF7 cells treated with the scFv antibody showed reduced STAT3 phosphorylation, decreased Bcl-2 expression, and increased Bax expression. Finally, the scFvs hindered EGFR and HER2 dimerization. The produced scFv antibody showed to be functional in a simultaneous blockade of EGFR and HER2, suggesting its potential as a promising candidate for targeted therapy against various EGFR overexpressing tumors. •The purified scFv demonstrated selective binding to EGFR-overexpressing cell line and inhibited EGFR/HER2 heterodimerization.•The findings suggest the therapeutic potential of anti-EGFR scFv antibodies in treating various cancers.•Evaluating antibodies targeting the EGFR family, demonstrating anti-proliferative, anti-tumor effects, and selective binding to overexpressing cells.•Engineered scFv induces apoptosis in cancer cells by modulating gene expression of Bcl-2 and Bax, offering promise for treating HER2-related cancers.
Bibliographie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1046-5928 1096-0279 1096-0279
DOI:	10.1016/j.pep.2024.106649